hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06368245, orgStudyIdInfo id: SMART, briefTitle: Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-15, primaryCompletionDateStruct date: 2027-12-15, completionDateStruct date: 2029-07-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: AO Foundation, AO Spine, class: OTHER, descriptionModule briefSummary: This is a multicenter retrospective comparative cohort study. The index surgery for this study is primary or revision long-segment posterior thoracolumbar (TL) instrumented fusion using either a supplementary rod construct or a dual-rod construct. Eligible patients who already had index surgery, will be identified for enrollment through a review of medical records of the participating surgeons at the study sites., conditionsModule conditions: Spinal Fusion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1244, type: ESTIMATED, armsInterventionsModule interventions name: long-segment posterior TL instrumented fusion, outcomesModule primaryOutcomes measure: Rod fracture (RF), secondaryOutcomes measure: Time to rod fracture, secondaryOutcomes measure: Time to rod fracture, secondaryOutcomes measure: Configurations of supplementary rod constructs, secondaryOutcomes measure: Treatment for rod fracture, secondaryOutcomes measure: Recurrent RFs, secondaryOutcomes measure: Other mechanical failures, secondaryOutcomes measure: Surgical complications, eligibilityModule sex: ALL, minimumAge: 45 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Minnesota Medical Center, city: Minneapolis, state: Minnesota, zip: 55454, country: United States, contacts name: David Polly, MD, role: CONTACT, email: pollydw@umn.edu, geoPoint lat: 44.97997, lon: -93.26384, locations facility: University of Virginia, city: Charlottesville, state: Virginia, zip: 22908, country: United States, contacts name: Justin S Smith, MD, PhD, role: CONTACT, phone: 434-243-6339, email: jss7f@virginia.edu, contacts name: Judith G Beenhakker, role: CONTACT, email: JGB3P@uvahealth.org, geoPoint lat: 38.02931, lon: -78.47668, hasResults: False
protocolSection identificationModule nctId: NCT06368232, orgStudyIdInfo id: 19.036.123.125, briefTitle: Nutritional Status After Sleeve Gastrectomy in Morbid Obesity: 6-Month Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-02-15, primaryCompletionDateStruct date: 2023-04-15, completionDateStruct date: 2023-04-15, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Ankara Yildirim Beyazıt University, class: OTHER, descriptionModule briefSummary: This study aims to evaluate the nutritional status of morbidly obese patients following gastric bypass surgery. Data from 76 patients aged 19-64, who will be monitored by a dietitian for at least six months, will be analyzed. Preoperative and postoperative biochemical parameters along with anthropometric measurements will assess., conditionsModule conditions: Bariatric Surgery Candidate, conditions: Gastrostomy, conditions: Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 76, type: ACTUAL, armsInterventionsModule interventions name: püPatients undergoing bariatric surgery, outcomesModule primaryOutcomes measure: Body Weight, primaryOutcomes measure: BMI (Body Mass Index), primaryOutcomes measure: Lean Mass, primaryOutcomes measure: Fat Mass, primaryOutcomes measure: Fasting Blood Glucose, primaryOutcomes measure: HbA1c, primaryOutcomes measure: Iron levels, primaryOutcomes measure: Vitamin D level, primaryOutcomes measure: Lipid Profile (Triglycerides, LDL, HDL), eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ankara Yıldırım Beyazıt University, city: Ankara, zip: 06760, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06368219, orgStudyIdInfo id: 0108161, briefTitle: Propofol or Benzodiazepine Combined With Ketamine for Procedural Sedation in Emergency Setting, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Alexandria University, class: OTHER, descriptionModule briefSummary: This single blinded parallel randomized clinical trial will be conducted on 50 patients presented to Emergency Department of Alexandria Main University Hospital who are indicated for procedural sedation. All patients included in the study will be allocated randomly using computer software with concealment of randomization in to two groups:* Group A: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg)* Group B: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg) Additional ketamine (0.25 mg/kg) will be administered in case of inadequate sedation in both groups.the two groups will be compared as regard incidence of complications World Society of Intravenous Anesthesia (SIVA) international sedation task force to standardize reporting adverse events, conditionsModule conditions: Procedural Sedation, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: ketamine- midazolam versus ketamine- propofol, outcomesModule primaryOutcomes measure: Induction and recovery time for both combinations, secondaryOutcomes measure: incidence and severity of adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06368206, orgStudyIdInfo id: OBPM_Calfree2024, briefTitle: Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring (OBPM) Device at Fingertip (Aktiia G2C) Against Double Auscultation, and Comparison With Oscillometry and Aktiia Bracelet G2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Aktiia SA, class: INDUSTRY, descriptionModule briefSummary: The present study, OBPM_Calfree2024, with N = 85 participants minimum over 1 visit (lasting around 1h), has been designed to evaluate the performances and safety of the Aktiia.product-G2C that doesn't require any calibrations, as compared against double auscultation for BP reference measurements, and finger pulse oximeter for pulse rate reference measurements, for a cohort of subjects characterized by a wide variety of phenotypes., conditionsModule conditions: Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: 1 study cohort that will test investigational device (Aktiia G2C) and Blood Pressure and Pulse Rate references., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 85, type: ESTIMATED, armsInterventionsModule interventions name: Investigational device Aktiia G2C, interventions name: Marketed device used as reference for blood pressure monitoring: double auscultation cuff, interventions name: Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2, interventions name: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff, interventions name: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff, interventions name: Marketed device used as reference for pulse rate monitoring: pulse finger oximeter, outcomesModule primaryOutcomes measure: Blood pressure mean value of differences, primaryOutcomes measure: Blood pressure standard deviation of differences, secondaryOutcomes measure: Pulse rate root-mean-square error, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHUV, city: Lausanne, zip: 1011, country: Switzerland, geoPoint lat: 46.516, lon: 6.63282, hasResults: False
protocolSection identificationModule nctId: NCT06368193, orgStudyIdInfo id: Neuralert 001, briefTitle: The Neuralert Stroke Monitor Pilot Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Neuralert Technologies LLC, class: INDUSTRY, descriptionModule briefSummary: This trial aims to demonstrate that the Neuralert Monitoring System will detect strokes before they would be identified by current standard of care. Each patient will be monitored for up to five days, depending on device connectivity or battery duration. Each monitoring session will consist of wearing a Neuralert device on each arm. For this pilot trial, we are interested in learning about Wi-Fi connectivity, successful data transmission, clinical usability, and tolerability., conditionsModule conditions: Stroke, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Neuralert Monitor, outcomesModule primaryOutcomes measure: Data Aggregation, secondaryOutcomes measure: Time to alarm reception, secondaryOutcomes measure: Time to alarm reponse, secondaryOutcomes measure: Stroke detection, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital of the University of Pennsylvania, city: Philadelphia, state: Pennsylvania, zip: 19104, country: United States, contacts name: Stephanie Cummings, role: CONTACT, phone: 215-662-3363, email: stephanie.cummings@pennmedicine.upenn.edu, contacts name: Scott Kasner, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06368180, orgStudyIdInfo id: 439106274, briefTitle: The Efficacy of a RAGT & BWSTT on Children With CP, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-08-30, primaryCompletionDateStruct date: 2021-02-21, completionDateStruct date: 2021-03-08, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: King Saud University, class: OTHER, descriptionModule briefSummary: This study compared the effects of RAGT and body weight support treadmill training (BWSTT) on spatio-temporal gait parameters and walking capacity among ambulatory children with bilateral CP, conditionsModule conditions: Cerebral Palsy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Robotic-assisted gait training Body weight-supported treadmill training, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Robotic assisted gait training, outcomesModule primaryOutcomes measure: Gait spatio-temporal parameters, secondaryOutcomes measure: Six-minute walk test (6MWT), eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 14 Years, stdAges: CHILD, contactsLocationsModule locations facility: King Abdu Aziz Medical City, city: Riyadh, country: Saudi Arabia, geoPoint lat: 24.68773, lon: 46.72185, hasResults: False
protocolSection identificationModule nctId: NCT06368167, orgStudyIdInfo id: SHR2554-202, briefTitle: A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Jiangsu HengRui Medicine Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma, conditionsModule conditions: Follicular Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 105, type: ESTIMATED, armsInterventionsModule interventions name: SHR2554, outcomesModule primaryOutcomes measure: Objective response rate (ORR) assessed by independent review committee (IRC), secondaryOutcomes measure: ORR assessed by investigator, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Time to Response, secondaryOutcomes measure: Duration of response, secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University Cancer Hospital, city: Beijing, state: Beijing, zip: 100142, country: China, contacts name: Yuqin Song, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06368154, orgStudyIdInfo id: HCHLL-2019-08, briefTitle: Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Hunan Children's Hospital, class: OTHER_GOV, descriptionModule briefSummary: Metabolic bone disease of prematurity (MBDP) is caused by insufficient content of calcium, phosphorus, and organic protein matrix in preterm infants or bone metabolism disorder, which is one of the complications affecting the quality of life of preterm infants. The early symptoms of MBDP are insidious, and there is no unified and clear diagnostic method. The diagnosis is mostly based on typical clinical manifestations and X-ray findings, but at this time, bone mineral density has decreased significantly, so early detection and diagnosis are difficult. Studies have shown that exosomal micrornas have biological characteristics and targeting specificity, and can be used as new molecular diagnostic markers for diseases. Several studies have reported the use of plasma or serum microRNAs as molecular markers for early prediction of bone diseases. In our previous study, we extracted plasma exosomes from preterm infants for high-throughput sequencing of microRNAs, and identified differentially expressed micrornas related to bone metabolism. In this study, exosomes were used as carriers, and digital PCR was used to verify the specificity and sensitivity of plasma exosomal microRNA as biomarkers of MBDP in a large sample size. The above biomarkers were compared and verified before and after treatment in children with MBDP. Further revealing plasma exosomal microRNA as a biological indicator for evaluating the efficacy of MBDP may improve the diagnostic level of MBDP, improve the outcome and prognosis of very low birth weight preterm infants, thereby improving global health and reducing socioeconomic costs., conditionsModule conditions: Exosomes, conditions: Newborn, conditions: Bone Diseases, Metabolic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: exosomes, eligibilityModule sex: ALL, minimumAge: 0 Hours, maximumAge: 72 Hours, stdAges: CHILD, contactsLocationsModule locations facility: Hunan Children's Hospital, status: RECRUITING, city: Changsha, state: Hunan, zip: 410007, country: China, contacts name: yinzhi y liu, master, role: CONTACT, phone: 13467532228, email: liuyinzhi0837@163.com, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06368141, orgStudyIdInfo id: 2023294, briefTitle: Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer, acronym: NeoCHIC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Ruijin Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn the effect of neoadjuvant chemotherapy plus sequential immune checkpoint inhibitor (ICI) therapy in locally advanced colon cancer. The main questions it aims to answer are:* Does this neoadjuvant chemotherapy increase the pathologic complete response (pCR) of locally advanced colon cancer?* Does this neoadjuvant chemotherapy improve the long-term survival of locally advanced colon cancer?Participants will receive:* a pre-operative CAPEOX (capecitabine oral + oxaliplatin i.v.)regimen.* a sequential CAPEOX plus Serplulimab regimen.* a standard complete mesocolic excision (CME) operation., conditionsModule conditions: Colon Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 56, type: ESTIMATED, armsInterventionsModule interventions name: Serplulimab, interventions name: Capecitabine, interventions name: Oxaliplatin, outcomesModule primaryOutcomes measure: pathologic complete response, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ruijin Hospital, city: Shanghai, state: Shanghai, zip: 200025, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06368102, orgStudyIdInfo id: R6-03, briefTitle: Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Uji Takeda Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine the incidence of surgical site infection (SSIs) after third molar surgery for different duration of intravenous ampicillin administration., conditionsModule conditions: Surgical Site Infection, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Ampicillin, outcomesModule primaryOutcomes measure: Occurrence of surgical site infection, secondaryOutcomes measure: Occurrence of alveolar osteitis, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06368089, orgStudyIdInfo id: REC.66-474-30-2, secondaryIdInfos id: MR-PSU:66-30-21-406, type: OTHER_GRANT, domain: Faculty of Medicine, Prince of Songkla University, briefTitle: Short Effects of SIMT and EM in Prolonged Mechanically Ventilated Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-02, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Prince of Songkla University, class: OTHER, descriptionModule briefSummary: Using mechanical ventilation for more than 18 hours can affect respiratory muscle and postural muscle control, making it difficult to wean off the ventilator and reducing mobility. The aim of this study is to:1. Compare the effects of respiratory muscle strength training and early mobilization on dynamic lung compliance and maximum inspiratory pressure before and after a 7-day training period.2. Compare the success rate of weaning and the duration of weaning between the respiratory muscle strength training and the early mobilization program., conditionsModule conditions: Ventilator Dependent, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomization, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Inspiratory muscle training (IMT) group, interventions name: Early mobilization (EM) group, outcomesModule primaryOutcomes measure: Maximum inspiratory pressure (MIP), primaryOutcomes measure: Dynamic lung compliance (Cdyn), secondaryOutcomes measure: Weaning time, secondaryOutcomes measure: Weaning outcome, secondaryOutcomes measure: Grip strength, secondaryOutcomes measure: chest wall expansion, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical Respiratory Care Unit (MRCU), Prince of Songklanakarind Hospital, city: Songkhla, zip: 90110, country: Thailand, geoPoint lat: 7.19882, lon: 100.5951, hasResults: False